ducovest

GEHC:NSD-GE HealthCare Technologies Inc. (USD)

COMMON STOCK | Health Information Services |

Last Closing

USD 87.2

Change

+1.93 (+2.26)%

Market Cap

USD 41.71B

Volume

4.70M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, X-ray systems, and women's health products. The Ultrasound segment provides medical devices and solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring solutions, anesthesia delivery and respiratory care products, electrocardiogram solutions, maternal infant care products, and consumables and services. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. It has an AI collaboration with Mass General Brigham. The company was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.

Company Website : https://www.gehealthcare.com

Currency: USD

Country : USA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-30 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
TEM Tempus AI, Inc. Class A Common..

+0.29 (+0.64%)

 USD 7.92B
HQY HealthEquity Inc

-0.90 (-1.03%)

 USD 7.65B
RCM R1 RCM Inc

+0.01 (+0.07%)

 USD 6.02B
WAY Waystar Holding Corp. Common S..

+0.46 (+1.64%)

 USD 4.47B
BTSG BrightSpring Health Services, ..

-0.95 (-5.97%)

 USD 2.71B
GDRX Goodrx Holdings Inc

-0.03 (-0.47%)

 USD 2.62B
PRVA Privia Health Group Inc

+0.76 (+4.23%)

 USD 2.09B
PINC Premier Inc

+0.12 (+0.60%)

 USD 2.00B
OMCL Omnicell Inc

+12.93 (+32.23%)

 USD 1.84B
CERT Certara Inc

-0.04 (-0.39%)

 USD 1.84B

ETFs Containing GEHC

UMDV:SW iShares US Medical Device.. 2.94 % 0.00 %

N/A

 N/A
WEBA:XETRA Amundi US Tech 100 Equal .. 1.19 % 0.00 %

-0.12 (-0.95%)

 USD 0.62B
CSD Invesco S&P Spin-Off ETF 0.00 % 1.16 %

+0.34 (+-0.95%)

 N/A
CSD Invesco S&P Spin-Off ETF 0.00 % 0.61 %

+0.34 (+-0.95%)

 N/A
IHI iShares U.S. Medical Devi.. 0.00 % 0.43 %

+0.24 (+-0.95%)

 N/A

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.78% 56% F 61% D-
Dividend Return -0.08% 100% F 99% N/A
Total Return 12.70% 56% F 62% D
Trailing 12 Months  
Capital Gain 27.71% 69% C- 59% D-
Dividend Return -0.09% 100% F 100% F
Total Return 27.62% 69% C- 59% D-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 6.07% 71% C- 57% F
Dividend Return 6.10% 71% C- 53% F
Total Return 0.03% 10% F 2% F
Risk Return Profile  
Volatility (Standard Deviation) 11.24% 98% N/A 87% B+
Risk Adjusted Return 54.33% 97% N/A 81% B-
Market Capitalization 41.71B 100% F 98% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.